2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

Elias Jabbour, Srdan Verstovsek, Francis Giles, Varsha Gandhi, Jorge Cortes, Susan O'Brien, William Plunkett, Guillermo Garcia-Manero, C. Ellen Jackson, Hagop Kantarjian, Michael Andreeff

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


BACKGROUND. Hypereosinophilic syndrome (HES) is a rare, disabling, and incurable disease. In this study, a combination of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (ara-C) chemotherapy was evaluated in patients with HES. METHODS. Nine patients with HES were treated with ara-C (1 g/m 2) given intravenously over 2 hours at 0 hours, 48 hours, 72 hours, 96 hours, and 120 hours; and 2-CdA (12 mg/m2 per day) was given as a continuous intravenous infusion over 5 days starting at 24 hours. A second course of the same therapy was administered in patients who had a response. RESULTS. All patients had signs and symptoms of end-organ involvement. The median time from diagnosis to therapy was 25 months. Seven patients had received prior therapies. Five patients (55%) achieved a complete remission (CR), 1 after receiving 2 courses of therapy. Elimination of eosinophilia was accompanied by the resolution of symptoms. The median disease-free survival and overall survival after the diagnosis for patients who achieved CR was 26 months and 44 months, respectively. Treatment was tolerated well. Febrile neutropenia occurred in 28% of the 14 courses that were given. The median time to recovery from neutropenia and thrombocytopenia was 17 days and 39 days, respectively. CONCLUSIONS. The combined 2-CdA and ara-C chemotherapy regimen had activity in patients with HES.

Original languageEnglish (US)
Pages (from-to)541-546
Number of pages6
Issue number3
StatePublished - Aug 1 2005
Externally publishedYes


  • 2-Chlorodeoxyadenosine
  • Chemotherapy
  • Cytarabine
  • Hypereosinophilic syndrome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of '2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome'. Together they form a unique fingerprint.

Cite this